For most people searching this question, the answer is tirzepatide, the drug sold as Mounjaro (for type 2 diabetes) and Zepbound (for weight loss). In head-to-head comparisons, tirzepatide produces roughly 14.7% body weight loss over two years compared to 10.8% with semaglutide, the active ingredient in Ozempic. That gap widens at higher thresholds of weight loss, and tirzepatide also outperforms semaglutide for blood sugar control. But “better” depends on what you need: more weight loss, fewer side effects, lower cost, or a needle-free option. Several alternatives and next-generation drugs are worth understanding.
Tirzepatide: The Strongest Available Option
Tirzepatide works on two gut hormone pathways instead of the single one Ozempic targets. Ozempic activates only GLP-1 receptors, which slow stomach emptying and reduce appetite. Tirzepatide hits both GLP-1 and GIP receptors, amplifying its effects on insulin, hunger, and fat metabolism. This dual action translates directly into bigger results.
In a large real-world study tracking patients over two years, tirzepatide users lost an average of 16 kg (about 35 pounds) compared to 11.6 kg (about 25.5 pounds) for semaglutide users. The differences become more striking when you look at who achieved major weight loss milestones. About 43% of people on tirzepatide lost 15% or more of their body weight, versus 22% on semaglutide. At the 20% threshold, it was 26% versus 12%. And 14% of tirzepatide patients reached 25% or greater weight loss, compared to just 5% on semaglutide.
Tirzepatide also works faster. Among high responders (those who lost at least 15% in the first year), the monthly rate of weight loss was 2.54% with tirzepatide versus 2.18% with semaglutide. Nearly twice as many tirzepatide users qualified as high responders: 42.6% compared to 21.6%.
Blood Sugar Control Comparison
If you’re managing type 2 diabetes, tirzepatide has a clear edge here too. In a head-to-head clinical trial, patients started with an average A1c of 8.28%. The highest dose of tirzepatide (15 mg) reduced A1c by 2.46 percentage points, while semaglutide 1 mg reduced it by 1.86 points. Even the lowest tirzepatide dose (5 mg) beat semaglutide, with a 2.09-point reduction. For context, that difference of roughly half a percentage point in A1c is clinically meaningful and can change whether someone reaches their target blood sugar range.
The Side Effect Tradeoff
Here’s where things get more complicated. Tirzepatide produces more gastrointestinal side effects than semaglutide. A meta-analysis of trials in people without diabetes found that about 80% of tirzepatide users experienced some form of GI issue (nausea, constipation, diarrhea, vomiting, or abdominal pain), compared to roughly 31% of semaglutide users. The placebo rates were 25% and 13%, respectively.
These numbers need some context. Most GI side effects are mild to moderate and concentrated during the dose-escalation period, when your body is adjusting to the medication. They tend to ease over time. But if you struggled with nausea on Ozempic, tirzepatide’s more aggressive profile is worth discussing with your prescriber. More weight loss comes with more gut disruption for many people.
CagriSema: A Combination Still in Development
One of the most promising next-generation options pairs semaglutide with cagrilintide, a long-acting version of a hormone called amylin that your pancreas naturally produces after meals. The combination, called CagriSema, is not yet FDA-approved but has shown impressive trial results.
In a systematic review and network meta-analysis, CagriSema ranked first for weight loss, A1c reduction, fasting blood sugar, blood pressure, and waist circumference when compared to either of its components alone. Perhaps more notably, it also had the best gastrointestinal tolerability profile, ranking lowest for nausea, vomiting, diarrhea, and side effects leading people to quit treatment. That combination of stronger results with fewer gut problems would represent a genuine leap forward if it holds up in larger trials and eventual approval.
Retatrutide: The Triple Agonist
Eli Lilly is developing retatrutide, which activates three hormone receptors: GLP-1, GIP, and glucagon. Adding glucagon receptor activation helps the body burn more energy and break down fat stores more aggressively. In a phase 3 trial for type 2 diabetes, participants on retatrutide lost an average of 36.6 pounds (16.8% of body weight) over 40 weeks. That’s a striking result for a relatively short treatment window, and weight loss was still trending downward when the measurement was taken. Retatrutide is still investigational and likely years from reaching pharmacies, but it signals where this drug class is heading.
Oral Semaglutide: Same Drug, No Needle
If your issue with Ozempic is the weekly injection rather than the drug itself, oral semaglutide (sold as Rybelsus for diabetes) offers the same active ingredient in pill form. Because the pill is absorbed less efficiently through the gut, it requires a much higher daily dose: 7 to 14 mg taken every day, compared to 1 to 2 mg injected once a week.
In a real-world study, the two formulations performed similarly over six months. Injectable semaglutide produced 6.5 kg of weight loss and a 1.1% A1c reduction, while the oral version produced 5.9 kg of weight loss and a 1.4% A1c reduction. Neither difference was statistically significant. The oral version requires strict dosing conditions: you take it on an empty stomach with no more than 4 ounces of plain water, then wait at least 30 minutes before eating or drinking anything else. That routine is a dealbreaker for some people but a fair trade for others who want to avoid injections.
Muscle Loss: A Concern With All GLP-1 Drugs
One underappreciated downside of every medication in this class is the amount of muscle lost alongside fat. Studies suggest that 25% to 39% of the total weight lost on GLP-1 drugs is lean mass (mostly muscle) over 36 to 72 weeks. That’s worse than the 10% to 30% lean mass loss seen with traditional calorie-restricted dieting, likely because the drugs produce more rapid and dramatic weight loss. On an annual basis, the muscle decline with these medications is several times greater than what would be expected from normal aging.
This matters because muscle mass protects your metabolism, bone density, and physical function as you age. No currently approved GLP-1 or dual agonist solves this problem on its own. Resistance training during treatment is the most practical way to offset muscle loss, and some clinicians are exploring protein intake targets or other interventions to help preserve lean tissue.
Cost Differences
As of recent list prices, a one-month supply of Ozempic runs about $936 in the U.S. Mounjaro (tirzepatide for diabetes) lists at $1,023, and Wegovy (semaglutide specifically approved for weight loss) costs $1,349. Rybelsus, the oral semaglutide tablet, is priced similarly to Ozempic at $936. Actual out-of-pocket costs vary enormously depending on insurance coverage, manufacturer savings programs, and whether you’re using the drug for diabetes or weight management. Many insurers cover diabetes indications more readily than weight loss.
Tirzepatide’s modest list price premium over Ozempic is notable given its substantially better results. If insurance covers both options equally, tirzepatide offers more weight loss per dollar. But coverage gaps and prior authorization requirements often dictate which drug you can realistically access, making “better” partly a question of what your plan will pay for.